课题基金 / 基金详情

Einstein Aging Study

Einstein Aging Study
爱因斯坦衰老研究
批准号:
10391027
负责人:
Richard B. LIPTON
金额:
$66.09万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-06-01 至 2022-03-31

项目摘要

项目成果

Richard B. LIPTON的其他基金

相关文献

中文摘要
翻译
摘要 爱因斯坦衰老研究(EAS)长期以来一直专注于预测衰老的风险因素和认知变化。 随后痴呆发作,特别是阿尔茨海默氏痴呆和相关痴呆(ADRD)。这项研究是 基于来自纽约州布朗克斯县的老年人的社区队列。在目前的融资期内,我们 开发了新的强化纵向方法来评估ADRD的认知状态和风险因素 采用生态瞬时评估(EMA)方法。这些改进了单次激发的一些局限性 基于临床的评估,提供日常生活中认知功能的测量, 认知功能的个体差异,以及“实时”捕获暴露数据, 回顾性召回新的流动措施与强大的基于临床的措施相结合, 认知表现、生物标志物、健康状况和健康行为,以识别早期认知变化, ADRD临床前阶段的下降和可改变的风险因素。 我们最近已就紧急援助计划的资助机会,提交了一份续期P01申请 PAR- 19-314(2021年1月25日),将通过利用移动的设备来捕获动态 当参与者从事日常活动时,风险因素和认知表现的时变性质 活动,以阐明联系行为,社会/情感和代谢健康的途径,以及 环境因素对早期认知能力下降的影响。利用EAS社区日益增加的多样性, 该项目的重点包括审查与认知健康方面的种族/族裔差异有关的社会因素。 为了实现P01的目标,重要的是保持EAS已建立的基础设施完好无损 (包括与参与者建立联系并帮助留住参与者的重要工作人员),继续全面 现有队列的特征,避免在确定结果和随时间变化的暴露方面存在差距, 保持数据质量,继续现有的合作,获取大脑并为EAS进行尸检 参与“尸检礼物”计划的人 EAS对认知老化研究做出了重大贡献。捐款以外 与项目目标相联系,多样化的、以社区为基础的群体被认为是一种宝贵的资源, 在许多国家和国际合作项目中。在这份补充文件中,我们要求桥梁资金 保持现有种族/族裔多样化群体的高保留率, 在考虑更新申请时,已建立的基础设施。目前的资金来源 期限至2021年5月31日。如果根据1月25日提交的申请获得资金,则开始日期不会开始 直到2021年12月1日。如有必要,根据PAR- 19-314重新提交的日期将在 2021年9月,开始日期为2021年6月1日。
英文摘要
Abstract The Einstein Aging Study (EAS) has long focused on the risk factors and cognitive changes that predict the subsequent onset of dementia, particularly Alzheimer’s dementia and related dementias (ADRD). The study is based on a community based cohort of older adults from Bronx County, NY. In the current funding period, we have developed novel intensive longitudinal methods to assess cognitive status and risk factors for ADRD using ecological momentary assessment (EMA) methods. These improve upon some limitations of single-shot clinic based assessments, providing measures of cognitive function in everyday life, enabling analyses of within person variability in cognitive function, and capturing data on exposures in “real-time” versus retrospective recall. The novel ambulatory measures are combined with robust clinic-based measures of cognitive performance, biomarkers, health status and health behaviors to identify early cognitive changes and decline and modifiable risk factors in the pre-clinical phase of ADRD. We have recently submitted a renewal P01 application for the EAS in response to the funding opportunity PAR- 19-314 (January 25, 2021) that will extend this work by utilizing mobile devices to capture the dynamic time-varying nature of risk factors and cognitive performance as participants engage in their usual daily activities in order to elucidate pathways linking behavioral, social/emotional and metabolic health, as well as environmental factors to early cognitive decline. Capitalizing on the increasing diversity of the EAS community, the project includes emphasis on examining social factors related to racial/ethnic disparities in cognitive health. In order to accomplish the P01s goals, it is important to keep intact the EAS established infrastructure (including valued staff who connect with participants and help with retention), continue the comprehensive characterization of the existing cohort, avoid gaps in ascertainment of outcomes and time varying exposures, maintain data quality, continue existing collaborations and obtain brains and perform autopsies for EAS participants in the ”Gift of Autopsy” program. The EAS has made significant contributions to cognitive aging research. Above and beyond contributions linked to project aims, the diverse, community-based cohort is recognized as a valuable resource that is used in numerous national and international collaborative projects. In this supplement, we request bridge funding to maintain high retention of the existing racially/ethnically diverse cohort and maintain the critically established infrastructure while the renewal application is under consideration. The current EAS funding period ends on May 31, 2021. If funded based on the January 25th submission, the start date would not begin until December 1, 2021. If necessary, the resubmission date in response to PAR- 19-314 would be in September, 2021, with a start date of June 1, 2021.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Migraine Clinical Outcome Assessment System (MiCOAS)
  • 批准号:
    10415455
  • 项目类别:
  • 资助金额:
    $31.31万
  • 财政年份:
    2019
  • 负责人:
    Richard B. LIPTON
  • 依托单位:
Migraine Clinical Outcome Assessment System (MiCOAS)
  • 批准号:
    10244980
  • 项目类别:
  • 资助金额:
    $162.88万
  • 财政年份:
    2019
  • 负责人:
    Richard B. LIPTON
  • 依托单位:
Migraine Clinical Outcome Assessment System (MiCOAS)
  • 批准号:
    10471249
  • 项目类别:
  • 资助金额:
    $113.01万
  • 财政年份:
    2019
  • 负责人:
    Richard B. LIPTON
  • 依托单位:
Einstein Center for Excellence for Clinical Trials in Neuroscience